Clinical development success rates for investigational drugs

被引：1626

作者：

Hay, Michael ^{[1
]}

Thomas, David W. ^{[2
]}

Craighead, John L. ^{[3
]}

Economides, Celia ^{[2
]}

Rosenthal, Jesse ^{[1
]}

机构：

[1] Sagient Res Syst, BioMedTracker, San Diego, CA 92122 USA

[2] BIO, Washington, DC USA

[3] Biotech Strategy & Analyt, Rockville, MD USA

来源：

NATURE BIOTECHNOLOGY | 2014年 / 32卷 / 01期

关键词：

PRODUCTIVITY; TRENDS; SCALE; RISKS; SCOPE;

D O I：

10.1038/nbt.2786

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The most comprehensive survey of clinical success rates across the drug industry to date shows productivity may be even lower than previous estimates.

引用

页码：40 / 51

页数：12

共 20 条

[1] Abrantes-Metz R.M., 2004, Pharmaceutical Development Phases: A Duration Analysis
[2] A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development
Arora, Ashish
Gambardella, Alfonso
Magazzini, Laura
Pammolli, Fabio
[J]. MANAGEMENT SCIENCE, 2009, 55 (10) : 1638 - 1653
[3] Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research
Cockburn, IM
Henderson, RM
[J]. JOURNAL OF HEALTH ECONOMICS, 2001, 20 (06) : 1033 - 1057
[4] Macro trends in pharmaceutical innovation
Cohen, FJ
[J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (01) : 78 - 84
[5] Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances
Danzon, PM
Nicholson, S
Pereira, NS
[J]. JOURNAL OF HEALTH ECONOMICS, 2005, 24 (02) : 317 - 339
[6] Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A.
Feldman, L.
Seckler, A.
Wilson, A.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) : 272 - 277
[7] Risks in new drug development: Approval success rates for investigational drugs
DiMasi, JA
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) : 297 - 307
[8] The price of innovation: new estimates of drug development costs
DiMasi, JA
Hansen, RW
Grabowski, HG
[J]. JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) : 151 - 185
[9] SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES
DIMASI, JA
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) : 1 - 14
[10] The Cost of Biopharmaceutical R&D: Is Biotech Different?
DiMasi, Joseph A.
Grabowski, Henry G.
[J]. MANAGERIAL AND DECISION ECONOMICS, 2007, 28 (4-5) : 469 - 479

← 1 2 →